Skip to main content

Table 2 In a multivariate analysis of breast cancer cases, the expression of YB-1 was better than HER-2 or ER in predicting reduced BCSS

From: Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes

Prognostic marker Patients with reduced BCSS
  HR (95% CI) P value
Nodal status   
   Positive versus negative 2.405 (2.083 to 2.776) 4.6 × 10-33
Tumor size (cm)   
   2 to 5 1.605 (1.387 to 1.859) 2.8 × 10-10
   >5 2.269 (1.749 to 2.943) 2.8 × 10-10
Grade   
   III versus II versus I 1.416 (1.215 to 1.651) 8.9 × 10-6
Age (years)   
   <50 versus = 50 1.160 (1.000 to 1.345) 5.0 × 10-2
ER   
   Positive versus negative 0.816 (0.720 to 0.991) 3.8 × 10-2
Her-2   
   Positive versus negative 1.259 (1.052 to 1.506) 1.2 × 10-2
YB-1   
   Positive versus negative 1.456 (1.257 to 1.656) 5.6 × 10-7
  1. YB-1 was approximately equal to the power of tumor grade yet not as accurate as tumor size or nodal status in predicting reduced BCSS. BCSS, breast cancer specific survival; CI, confidence interval; ER, estrogen receptor; HER, human epidermal growth factor receptor; HR, hazard ratio; YB-1 = Y-box binding protein-1.